| 非酒精性脂肪肝病大鼠肝脏SOCS-3 的表达与吡格列酮干预研究 |
| |
| 引用本文： | 曹彦,易艳荣.非酒精性脂肪肝病大鼠肝脏SOCS-3 的表达与吡格列酮干预研究[J].现代生物医学进展,2011,11(10):1817-1820. |
| |
| 作者姓名： | 曹彦 易艳荣 |
| |
| 作者单位： | 1. 湖南省人民医院急诊科,湖南,长沙,410005
2. 长沙市中心医院消化内科,湖南,长沙,410004 |
| |
| 摘 要： | 目的:探讨SOCS-3在非酒精性脂肪肝病(NAFLD)发病中的作用以及吡格列酮的干预作用。方法:29只雄性SD大鼠随机分为正常对照组(8只),高脂饮食组(21只)。饲养8周后,从高质饮食组随机抽取5只大鼠证实造模成功后,将该组余下的16只大鼠继续以高脂饲料喂养,并随机分为NAFLD对照组(8只);吡格列酮干预组(8只),予以吡格列酮3mg·kg-·1d-1灌胃。16周末,处死所有大鼠,检测血糖、血胰岛素、血脂、肝脏SOCS-3 mRNA和SREBP-1c mRNA表达及肝脏病理学。结果:与正常对照组相比,NAFLD组血糖、血胰岛素、血脂、肝脏脂肪变水平及肝组织SOCS-3 mRNA、SREBP1c mRNA表达显著上调。吡格列酮干预组SOCS-3 mRNA、SREBP-1c mRNA表达较NAFLD组下调,且血糖、血胰岛素、血脂、肝脏脂肪变水平下降。SOCS-3 mRNA表达水平与胰岛素抵抗指数、SREBP-1c mRNA表达水平、肝脂肪变成显著正相关。结论:SOCS-3可能通过胰岛素抵抗及上调肝组织SREBP-1c mRNA表达参与NAFLD发病,吡格列酮能抑制肝脏SOCS-3的表达,对NAFLD有一定治疗作用。
|
| 关 键 词： | 非酒精性脂肪肝病 SOCS-3 吡格列酮 |
Expression of SOCS-3 in the Liver of Rats with Nonalcoholic Fatty Liver
Disease and Therapeutic Effects of Pioglitazone |
| |
| CAO Yan,YI Yan-rong.Expression of SOCS-3 in the Liver of Rats with Nonalcoholic Fatty Liver
Disease and Therapeutic Effects of Pioglitazone[J].Progress in Modern Biomedicine,2011,11(10):1817-1820. |
| |
| Authors: | CAO Yan YI Yan-rong |
| |
| Institution: | CAO Yan1,YI Yan-rong2(1 Department of Emergency,Hunan Province People's Hospital,410005,Changsha,China,2 Department of Digestion,Changsha Central Hospital,410004,China) |
| |
| Abstract: | Objective:To investigate the role of suppressors of cytokine signaling protein(SOCS-3) in the pathogenesis of patients with nonalcoholic fatty liver as well as the effects of pioglitazone.Methods:Twenty-nine male SD rats were randomized into normal control group(n=8,fed with normal food),high fat diet group(n=21,fed with fat-rich food).Killed 5 rats of high fat diet group after 8 weeks,and confirmed that the model of NAFLD was successfully established.Then the remaining 16 rats were divided into 2 subgroups... |
| |
| Keywords: | SOCS-3 |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《现代生物医学进展》浏览原始摘要信息 |
| 点击此处可从《现代生物医学进展》下载免费的PDF全文 |
|
